[1] |
VARGHESE R T, JIALAL I. Diabetic Nephropathy[M]. StatPearls. Treasure Island(FL): StatPearls Publishing Copyright© 2023,StatPearls Publishing LLC,2023.
|
[2] |
ZHAO Z H, HUO L L, WANG L Y, et al. Survival of Chinese people with type 2 diabetes and diabetic kidney disease:a cohort of 12-year follow-up[J]. BMC Public Health, 2019, 19(1):1498. doi:10.1186/s12889-019-7859-x.
|
[3] |
YUE S R, LI S S, HUANG X Y, et al. Machine learning for the prediction of acute kidney injury in patients with sepsis[J]. J Transl Med, 2022, 20(1):215. doi:10.1186/s12967-022-03364-0.
|
[4] |
ABEGAZ T M, BALJOON A, KILANKO O, et al. Machine learning algorithms to predict major adverse cardiovascular events in patients with diabetes[J]. Comput Biol Med, 2023,164:107289. doi:10.1016/j.compbiomed.2023.107289.
|
[5] |
中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2020年版)[J]. 中华糖尿病杂志, 2021, 13(4):315-409.
|
|
Chinese Diabetes Society. Guideline for the prevention and treatment of type 2 diabetes mellitus in China(2020 edition)[J]. Chin J Diabetes Mellitus, 2021, 13(4):315-409. doi:10.3760/cma.j.cn115791-20210221-00095.
|
[6] |
中华医学会糖尿病学分会微血管并发症学组. 中国糖尿病肾脏病防治指南(2021年版)[J]. 中华糖尿病杂志, 2021, 13(8):762-784.
|
|
Microvascular Complications Group of Chinese Diabetes Society. Clinical guideline for the prevention and treatment of diabetic kidney disease in China(2021 edition)[J]. Chin J Diabetes Mellitus, 2021, 13(8):762-784. doi:10.3760/cma.j.cn115791-20210706-00369.
|
[7] |
PERKINS B A, BEBU I, DE BOER I H, et al. Risk factors for kidney disease in type 1 diabetes[J]. Diabetes Care, 2019, 42(5):883-890. doi:10.2337/dc18-2062.
|
[8] |
XU B, LI S Q, KANG B, et al. The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management[J]. Cardiovasc Diabetol, 2022, 21(1):83. doi:10.1186/s12933-022-01512-w.
|
[9] |
ZOU Y T, ZHAO L J, ZHANG J L, et al. Development and internal validation of machine learning algorithms for end-stage renal disease risk prediction model of people with type 2 diabetes mellitus and diabetic kidney disease[J]. Ren Fail, 2022, 44(1):562-570. doi:10.1080/0886022x.2022.2056053.
|
[10] |
LIU W, DU J, GE X X, et al. The analysis of risk factors for diabetic kidney disease progression:a single-centre and cross-sectional experiment in Shanghai[J]. BMJ Open, 2022, 12(6):e060238. doi:10.1136/bmjopen-2021-060238.
|
[11] |
YANAGAWA T, KOYANO K, AZUMA K. Retrospective study of factors associated with progression and remission/regression of diabetic kidney disease-hypomagnesemia was associated with progression and elevated serum alanine aminotransferase levels were associated with remission or regression[J]. Diabetol Int, 2021, 12(3):268-276. doi:10.1007/s13340-020-00483-1.
|
[12] |
PETROFF D, BÄTZ O, JEDRYSIAK K, et al. Age dependence of liver enzymes:an analysis of over 1,300,000 consecutive blood samples[J]. Clin Gastroenterol Hepatology, 2022, 20(3):641-650. doi:10.1016/j.cgh.2021.01.039.
|
[13] |
FELÍCIO J S, DE RIDER BRITTO H A, CORTEZ P C, et al. Association between 25(OH)vitamin D,HbA1c and albuminuria in diabetes mellitus:data from a population-based study (VIDAMAZON)[J]. Front Endocrinol (Lausanne), 2021,12:12723502. doi:10.3389/fendo.2021.723502.
|
[14] |
XU F, LU H Y, LAI T W, et al. Association between vitamin D status and mortality among adults with diabetic kidney disease[J]. J Diabetes Res, 2022,2022:9632355. doi:10.1155/2022/9632355.
|
[15] |
HUANG H Y, LIN T W, HONG Z X, et al. Vitamin D and diabetic kidney disease[J]. Int J Mol Sci, 2023, 24(4):3571. doi:10.3390/ijms24043751.
|
[16] |
NISHAD R, MUKHI D, KETHAVATH S, et al. Podocyte derived TNF-α mediates monocyte differentiation and contributes to glomerular injury[J]. FASEB J, 2022, 36(12):e22622. doi:10.1096/fj.202200923R.
|
[17] |
许莉敏, 谢燕. 外周血单核细胞DNMT1及血清IL-6在糖尿病肾脏病中的表达及意义[J]. 天津医药, 2023, 51(2):194-198.
|
|
XU L M, XIE Y. Expression and significance of peripheral blood mononuclear cell DNMT1 and serum IL-6 in diabetic nephropathy[J]. Tianjin Med J, 2023, 51(2):194-198. doi:10.11958/20220812.
|
[18] |
ZENG H X, QI X M, XU X X, et al. TAB1 regulates glycolysis and activation of macrophages in diabetic nephropathy[J]. Inflamm Res, 2020, 69(12):1215-1234. doi:10.1007/s00011-020-01411-4.
|
[19] |
OPAZO-RÍOS L, MAS S, MARÍN-ROYO G, et al. Lipotoxicity and diabetic nephropathy: novel mechanistic insights and therapeutic opportunities[J]. Int J Mol Sci, 2020, 21(7):2632. doi:10.3390/ijms21072632.
|
[20] |
YU K P, LI D R, XU F P, et al. IDO1 as a new immune biomarker for diabetic nephropathy and its correlation with immune cell infiltration[J]. Int Immunopharmacol, 2021,94:107446. doi:10.1016/j.intimp.2021.107446.
|